Taylor Wessing advised Shield Therapeutics plc on the deal.Shield Therapeutics plc, an AIM-listed commercial stage specialty pharmaceutical company, extended an existing convertible debt facility by $10 million…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
